Avelox

Product manufactured by Redpharm Drug Inc.

Approved Date Route External Links
2011-08-08 Oral Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage To Reduce The Development Of Drug-Resistant Bacteria And Maintain The Effectiveness Of Avelox And Other Antibacterial Drugs, Avelox Should Be Used Only To Treat Or Prevent Infections That Are Proven Or Strongly Suspected To Be Caused By Susceptible Bacteria. When Culture And Susceptibility Information Are Available, They Should Be Considered In Selecting Or Modifying Antibacterial Therapy. In The Absence Of Such Data, Local Epidemiology And Susceptibility Patterns May Contribute To The Empiric Selection Of Therapy. Avelox Tablets And Iv Are Indicated For The Treatment Of Adults (≥ 18 Years Of Age) With Infections Caused By Susceptible Strains Of The Designated Microorganisms In The Conditions Listed Below [see Dosage And Administration (2) And Use In Specific Populations (8.5)]. Culture And Susceptibility Testing Appropriate Culture And Susceptibility Tests Should Be Performed Before Treatment In Order To Isolate And Identify Organisms Causing Infection And To Determine Their Susceptibility To Moxifloxacin [see Clinical Pharmacology (12.4)]. Therapy With Avelox May Be Initiated Before Results Of These Tests Are Known; Once Results Become Available, Appropriate Therapy Should Be Continued. Avelox Is A Fluoroquinolone Antibacterial Indicated For Treating Infections In Adults ≥ 18 Years Of Age Caused By Designated, Susceptible Bacteria. (1, 12.4) Acute Bacterial Sinusitis (1.1) Acute Bacterial Exacerbation Of Chronic Bronchitis (1.2) Community Acquired Pneumonia (1.3) Skin And Skin Structure Infections: Uncomplicated (1.4) And Complicated (1.5) Complicated Intra-Abdominal Infections (1.6) 1.1 Acute Bacterial Sinusitis Avelox Is Indicated For The Treatment Of Acute Bacterial Sinusitis Caused By Streptococcus Pneumoniae, Haemophilus Influenzae, Or Moraxella Catarrhalis [see Clinical Studies (14.4)]. 1.2 Acute Bacterial Exacerbation Of Chronic Bronchitis Avelox Is Indicated For The Treatment Of Acute Bacterial Exacerbation Of Chronic Bronchitis Caused By Streptococcus Pneumoniae, Haemophilus Influenzae, Haemophilus Parainfluenzae, Klebsiella Pneumoniae, Methicillin-Susceptible Staphylococcus Aureus, Or Moraxella Catarrhalis [see Clinical Studies (14.1)]. 1.3 Community Acquired Pneumonia Avelox Is Indicated For The Treatment Of Community Acquired Pneumonia Caused By Streptococcus Pneumoniae (including Multi-Drug Resistant Strains*), Haemophilus Influenzae, Moraxella Catarrhalis, Methicillin-Susceptible Staphylococcus Aureus, Klebsiella Pneumoniae, Mycoplasma Pneumoniae, Or Chlamydophilia Pneumoniae. * Mdrsp, Multi-Drug Resistant Streptococcus Pneumoniae Includes Isolates Previously Known As Prsp (penicillin-Resistant S. Pneumoniae), And Are Strains Resistant To Two Or More Of The Following Antibiotics: Penicillin (minimum Inhibitory Concentrations [mic] ≥ 2 Mcg/ml), 2nd Generation Cephalosporins (for Example, Cefuroxime), Macrolides, Tetracyclines, And Trimethoprim/sulfamethoxazole [see Clinical Studies (14.2)]. 1.4 Uncomplicated Skin And Skin Structure Infections Avelox Is Indicated For The Treatment Of Uncomplicated Skin And Skin Structure Infections Caused By Methicillin-Susceptible Staphylococcus Aureus Or Streptococcus Pyogenes [see Clinical Studies (14.5)]. 1.5 Complicated Skin And Skin Structure Infections Avelox Is Indicated For The Treatment Of Complicated Skin And Skin Structure Infections Caused By Methicillin-Susceptible Staphylococcus Aureus, Escherichia Coli, Klebsiella Pneumoniae, Or Enterobacter Cloacae [see Clinical Studies (14.6)]. 1.6 Complicated Intra-Abdominal Infections Avelox Is Indicated For The Treatment Of Complicated Intra-Abdominal Infections Including Polymicrobial Infections Such As Abscess Caused By Escherichia Coli, Bacteroides Fragilis, Streptococcus Anginosus, Streptococcus Constellatus, Enterococcus Faecalis, Proteus Mirabilis, Clostridium Perfringens, Bacteroides Thetaiotaomicron, Or Peptostreptococcus Species [see Clinical Studies (14.7)].

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Moxifloxacin Hydrochloride MOXIFLOXACIN HYDROCHLORIDE ZINC3826253

Comments